Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

Forward-Looking Statements: Cytokinetics

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' collaboration with Amgen, including potential milestone payments and other payments and funding and the expected roles of Cytokinetics and Amgen under the collaboration and in developing or commercializing drug candidates or drugs subject to the collaboration; statements relating to the clinical development of CK-1827452, including the initiation, design, enrollment, conduct and results of clinical trials and the significance of such results, and planned presentations relating to clinical trial results; the size and growth of expected markets fo
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... BRIARCLIFF MANOR, N.Y., Dec. 15 The ... announced that the professional society is continuing to ... is being held in Arlington, VA, April 19-21, ... society is encouraging non-members to join the organization ... event. The submission deadline is 12 AM EST, ...
(Date:12/15/2009)... 15 , ... Evaluate the Ability of,Cardiopoietic Cells to Restore Cardiac ... a leading Belgian biotechnology company specialising,in cell-based therapies ... it has completed, two months ahead of schedule,enrolment ... II/III trial of C-Cure, a,unique stem cell therapy ...
(Date:12/14/2009)... Fla., Dec. 14 Dyadic International, Inc. ... has extended its collaboration with The Scripps Research ... Scripps to re-annotate the genome of Dyadic,s patented ... is a continuation of the successful relationship between ... when Dyadic engaged Scripps to annotate the C1 ...
(Date:12/14/2009)... Dec. 14 Lionbridge (Nasdaq: ... signed a new, three-year master services agreement ... products and services that serve patients in ... will become the sole provider for translation ... regulatory, marketing, training, human resources, legal, and ...
Breaking Biology Technology:The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3
... D facilities for Ap3ana, CTI,s ,personalized medicine, venture, ... (CTI),(Nasdaq: CTIC ) announced today that Christina ... of a Tyr Pharma and formerly Director of,Scientific ... has been named President of CTI Europe. Based ...
... (TSX; FSE: HBP) today announced that it has closed ... units at $1.68 per,unit, for gross proceeds totaling CDN$11,424,000., ... one-half of one common share,purchase warrant, with each whole ... to adjustment, one common share at a price,of $2.36 ...
... Business Update to Investors, WILMINGTON, Del., Oct. ... Vice President & General Manager John Ranieri,said the ... programs to,market are on track and making significant ... conversion of cellulosic feedstocks,economically into biofuels., "Biobutanol ...
Other Biology Technology:Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
(Date:12/16/2009)... December 15, 2009 Signal Hill, CA Tom ... public and president of Bowman Global Change, has developed ... the fourth Intergovernmental Panel on Climate Change (IPCC) report ... to the authentic scientific information they need to make ... Bowman created the new format as a means to ...
(Date:12/16/2009)... PALM HARBOR, Fla., Dec. 2 ... CICI), a leading supplier of electronic signature ... financial industry* and the recognized leader** in ... ("Docubase"), a leading International Electronic Document Management ... have entered an agreement to provide their ...
(Date:12/16/2009)... CHURCH, Va., Dec. 9 CSC ... that the American Association for Laboratory Accreditation ... Commission (ISO/IEC) 17025:2005 accreditation to the company,s ... CSC Identity Labs located in Fairmont, W.Va. ... test laboratory in the world to achieve ...
Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Former Associates File Suit Against Univera 3A Dietary Supplement Company Accused of Intimidation Bullying and Unfair Trade Practices 50104 1Former Associates File Suit Against Univera 3A Dietary Supplement Company Accused of Intimidation Bullying and Unfair Trade Practices 50104 2Too Few Americans Get HIV Test Early Enough 50100 1Too Few Americans Get HIV Test Early Enough 50100 2Too Few Americans Get HIV Test Early Enough 50100 3UnitedHealthcare and Fusion Sleep Announce New Agreement 50096 1UnitedHealthcare and Fusion Sleep Announce New Agreement 50096 2
... mini-foods, especially if you,re a dieter. , Chronic ... packages are smaller, according to a new study in ... L. Scott, Stephen M. Nowlis, Naomi Mandel, and Andrea ... regarding "mini-packs," 100-calorie food packages that are marketed to ...
... release is available in German . , ... Allergy and the Center for Allergy and Environment of ... Mnchen have pinpointed a major gene for allergic diseases. ... examining the whole human genome at the Helmholtz Zentrum ...
... University and the University of St. Andrews, United Kingdom, have ... or may not easily cause a recollection of other associated, ... the way in which the learned information is forgotten. ... PLoS Computational Biology . , When one learns a language ...
Other Biology News:M&Ms as diet food? 100-calorie pack misconceptions 2Munich researchers discover key allergy gene 2
MAb to Myoglobin Cardiac...
... valuable tool for removing SDS detergent from ... in biological samples imparts a negative charge ... enzymatic activity during digestion, and suppresses ion ... mass spectrometry analyses. We recommend that ...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Biology Products: